Novartis announced the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending approval of Kymriah (tisagenlecleucel, formerly CTL019)—a one-time treatment that uses a patient’s own T cells to fight cancer.
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
